e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary technology based on advances in network pharmacology and chemical biology. The company is focused on the discovery and out-licensing of effective new medicines for bio-complex diseases.
The company’s technology offers new insights in discovery and development programmes by capturing the complexity and vulnerabilities of disease-related networks. Molecules are selected based on their chemical biology “footprint”, using proprietary in silico modelling prior to confirming predicted activity is cellular assays. This approach focuses on identifying molecules with maximum impact in the target disease network rather than a single target approach..
Our discovery platform is highly productive, yielding multiple potent and selective molecules at a much higher rate, more quickly, than is reported for conventional drug discovery. As much of the discovery process is performed in silico, it is possible to go from project initiation to the commencement of medicinal chemistry in nine months.
Working in collaboration with partners, e-Therapeutics can de-risk investment in new drugs and make a fundamental difference in the selection of the most effective candidates.
The company is focused on those illnesses associated with bio-complexity whose prevalence rises with age, including cancer. However, the technology is applicable to many other disease states and we have programmes in other areas such as antivirals.
- Invesco – 84,524,060 (31.99%)
- Richard Griffiths and controlled undertakings – 56,767,667 (21.15%)
- Woodford Asset Management – 46,807,479 (17.7%)
- Lombard Odier Asset Management (Europe) Limited – 35,560,283 (12.13%)
- Octopus Group – 11,097,658 (4.2%)